Near-Infrared Light-Triggered NO/Photodynamic Synergistic
Therapy with Antibacterial and Biofilm-Eliminated Effects for Difficult-to-Treat
Rhinosinusitis
posted on 2024-02-02, 14:36authored byLuxuan Liu, Kai Lv, Xidong Wu, Guangyuan Dong, Yan Ge, Yiran Shao, Guowei Li, Dong Ma, Tao Liu
Chronic
rhinosinusitis (CRS) is a complex condition that affects
an individual’s well-being and quality of life. While there
are current treatment options like medication and surgery, an increasing
number of patients experience difficult-to-treat rhinosinusitis (DTRS).
To address this challenge, a highly efficient intelligent nanoplatform
(ALCe6 NPs) has been developed, which is formed by loading chlorin
e6 (Ce6) onto nanoliposomes composed of cholesterol modified with l-arginine and soybean phospholipids. Under near-infrared (NIR)
light stimulation, Ce6 is efficiently activated to generate reactive
oxygen species (ROS), leading to the controlled release of nitric
oxide (NO). This synergistic effect of ROS generated from photodynamic
therapy (PDT) and NO release enables the dispersion of bacterial biofilms
and the effective eradication of drug-resistant bacteria. Genome analysis
of the combined antibacterial action of ALCe6 NPs reveals changes
in genes related to cellular metabolism, transcription processes,
and bacterial resistance. To evaluate the therapeutic efficacy of
ALCe6 NPs in treating DTRS caused by methicillin-resistant Staphylococcus aureus (MRSA) infection, a rat model
is constructed to monitor the treatment process and assess the outcomes.
With its significant advantages, ALCe6 NPs show promising potential
as a biomedical tool to combat drug-resistant bacterial infections
in vivo, offering hope for managing DTRS and improving patient outcomes.